Key Points
- Major shareholder Group Walters bought 4.335 million Zentalis Pharmaceuticals shares at $3.50 each, investing approximately $15.2 million and increasing its position by 32.1% to 17.84 million shares.
- ZNTL shares were trading at $3.82, while the company recently reported a quarterly loss of $0.59 per share—$0.10 worse than analysts expected. Analysts project a full-year loss of $2.14 per share.
- Analyst sentiment is mixed, with a consensus “Hold” rating and an average price target of $6.75; several firms remain bullish, while others maintain sell or strong-sell views.
Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Get Free Report) major shareholder Group Walters acquired 4,335,000 shares of the company's stock in a transaction that occurred on Friday, August 14th. The stock was purchased at an average price of $3.50 per share, for a total transaction of $15,172,500.00. Following the purchase, the insider owned 17,844,973 shares of the company's stock, valued at $62,457,405.50. The trade was a 32.09% increase in their position. The purchase was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Large shareholders that own 10% or more of a company's shares are required to disclose their sales and purchases with the SEC.
Zentalis Pharmaceuticals Trading Up 3.8%
Shares of NASDAQ ZNTL opened at $3.82 on Thursday. The stock has a fifty day simple moving average of $4.34 and a two-hundred day simple moving average of $3.66. Zentalis Pharmaceuticals, Inc. has a 1-year low of $1.21 and a 1-year high of $6.95. The firm has a market cap of $273.78 million, a price-to-earnings ratio of -1.96 and a beta of 1.92.
Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its earnings results on Thursday, August 6th. The company reported ($0.59) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.49) by ($0.10). Analysts forecast that Zentalis Pharmaceuticals, Inc. will post -2.14 EPS for the current year.
Institutional Trading of Zentalis Pharmaceuticals
A number of institutional investors have recently added to or reduced their stakes in ZNTL. 5AM Venture Management LLC bought a new position in Zentalis Pharmaceuticals in the 2nd quarter worth about $19,147,378,000. BlackRock Inc. bought a new stake in shares of Zentalis Pharmaceuticals during the second quarter valued at about $18,205,000. Millennium Management LLC increased its position in shares of Zentalis Pharmaceuticals by 220.6% during the first quarter. Millennium Management LLC now owns 3,069,514 shares of the company's stock valued at $4,881,000 after buying an additional 2,111,951 shares during the period. Ishara Investments LP purchased a new stake in shares of Zentalis Pharmaceuticals in the fourth quarter worth about $1,782,000. Finally, Bank of America Corp DE purchased a new stake in shares of Zentalis Pharmaceuticals in the second quarter worth about $5,406,000.
Analyst Upgrades and Downgrades
A number of brokerages recently issued reports on ZNTL. HC Wainwright restated a "buy" rating and issued a $10.00 price objective on shares of Zentalis Pharmaceuticals in a research note on Friday, May 22nd. Mizuho began coverage on shares of Zentalis Pharmaceuticals in a research report on Friday, July 17th. They set an "outperform" rating and a $8.00 target price for the company. Rodman & Renshaw assumed coverage on shares of Zentalis Pharmaceuticals in a research note on Thursday, July 23rd. They issued a "buy" rating and a $11.00 target price for the company. Wall Street Zen lowered shares of Zentalis Pharmaceuticals from a "sell" rating to a "strong sell" rating in a research report on Saturday, August 8th. Finally, Weiss Ratings restated a "sell (d-)" rating on shares of Zentalis Pharmaceuticals in a research note on Monday, July 6th. Four research analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company presently has a consensus rating of "Hold" and an average target price of $6.75.
Read Our Latest Research Report on ZNTL
About Zentalis Pharmaceuticals
(
Get Free Report)
Zentalis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapeutics for oncology. Leveraging a proprietary structure-based drug discovery platform, the company designs selective inhibitors aimed at critical cancer targets. Zentalis' research and development efforts center on delivering differentiated therapies that address unmet medical needs in solid tumors and hematologic malignancies.
The company's lead product candidate, ZN-c3, is an orally administered inhibitor of the p53-MDM2 interaction, currently being evaluated in Phase I clinical trials for advanced solid tumors and hematologic cancers.
Read More
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
